Download PDF
Fortschr Neurol Psychiatr 2013; 81(2): 104-118
DOI: 10.1055/s-0032-1330403
Fort- und Weiterbildung
© Georg Thieme Verlag KG Stuttgart · New York

Differenzialindikation von Antidepressiva

Individualized Treatment with Antidepressants
S. Köhler
1   Klinik für Psychiatrie und Psychotherapie, Charité, Berlin
,
A. Arndt
1   Klinik für Psychiatrie und Psychotherapie, Charité, Berlin
,
P. Sterzer
1   Klinik für Psychiatrie und Psychotherapie, Charité, Berlin
,
T. Bschor
2   Klinik für Psychiatrie, Schlosspark-Klinik, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
14 February 2013 (online)

    Permissions and Reprints

Lernziele

Ziel dieses Artikels ist es, Vor- und Nachteile verschiedener Antidepressiva auf Grundlage komplexer Behandlungssituationen wie komorbiden Erkrankungen und pharmakologischen Besonderheiten über normales Lehrbuchwissen hinaus zu identifizieren. Damit sollen individualisierte Therapiestrategien aufgezeigt werden, die evtl. Vorteile gegenüber der Standardbehandlung haben. Diese beinhalten eine individualisierte Monotherapie, pharmakologisch sinnvolle Kombinationstherapien und adjuvante Behandlungsoptionen.

 

  • Literatur

  • 1 Kaptchuk TJ. The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?. J Clin Epidemiol 2001; 54: 541-549
    CrossrefPubMedGoogle Scholar
  • 2 DGPPN, BÄK, KBV et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. 23.09.2010 cited 2009 Available from: www.dgppn.de, www.versorgungsleitlinien.de, www.awmf-leitlinien.de
    PubMedGoogle Scholar
  • 3 Härter M, Klesse C, Bermejo I et al. Unipolar depression: diagnostic and therapeutic recommendations from the current S3/National Clinical Practice Guideline. Dtsch Arztebl Int 2010; 107: 700-708
    PubMedGoogle Scholar
  • 4 Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-758
    CrossrefPubMedGoogle Scholar
  • 5 Turner E, Moreno SG, Sutton AJ. Ranking antidepressants. Lancet 2009; 373: 1760 ; author reply 1761–1762
    CrossrefPubMedGoogle Scholar
  • 6 Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry 2005; 66: 1409-1414
    CrossrefPubMedGoogle Scholar
  • 7 Benkert O, Hippius H. Antidepressiva, in Kompendium der Psychiatrischen Pharmakotherapie. Heidelberg: Springer; 2011: 1-132
    CrossrefGoogle Scholar
  • 8 Lotufo-Neto F, Bernik M, Ramos RT et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol 2001; 15: 13-17
    CrossrefPubMedGoogle Scholar
  • 9 Mavissakalian MR. Imipramine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry 2003; 15: 171-180
    CrossrefPubMedGoogle Scholar
  • 10 Davidson JR, Foa EB, Huppert JD et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004; 61: 1005-1013
    CrossrefPubMedGoogle Scholar
  • 11 Albert U, Aguglia E, Maina G et al. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63: 1004-1009
    CrossrefPubMedGoogle Scholar
  • 12 Bloch MH, McGuire J, Landeros-Weisenberger A et al. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry 2010; 15: 850-855
    CrossrefPubMedGoogle Scholar
  • 13 Bisson JI. Post-traumatic stress disorder. Clin Evid 2010; (Online)
    PubMedGoogle Scholar
  • 14 Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009; 4: CD007115
    PubMedGoogle Scholar
  • 15 Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007; 4: CD005454
    PubMedGoogle Scholar
  • 16 Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010; 71: 754-763
    CrossrefPubMedGoogle Scholar
  • 17 O’Brien S, Rapkin A, Dennerstein L et al. Diagnosis and management of premenstrual disorders. BMJ 2011; 342: d2994
    CrossrefPubMedGoogle Scholar
  • 18 Raupach T, van Schayck CP. Pharmacotherapy for smoking cessation: current advances and research topics. CNS Drugs 2011; 25: 371-382
    CrossrefPubMedGoogle Scholar
  • 19 Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry 2011; 72: 156-167
    CrossrefPubMedGoogle Scholar
  • 20 Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006; 8: 478-488
    CrossrefPubMedGoogle Scholar
  • 21 Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 2002; 19: 299-320
    CrossrefPubMedGoogle Scholar
  • 22 Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int 2011; 108: 687-693
    Google Scholar
  • 23 Cobos EJ, Entrena JM, Nieto FR et al. Pharmacology and therapeutic potential of sigma (1) receptor ligands. Curr Neuropharmacol 2008; 6: 344-366
    CrossrefPubMedGoogle Scholar
  • 24 Sadock BJ, Sadock VA. Behavioral Sciences/Clinical Psychiatry. In: Kaplan and Sadock’s Synopsis of Psychiatry. Philadelphia: Lippincott Williams and Wilkins; 2007: 977-1126
    Google Scholar
  • 25 Tang SW, Helmeste D. Paroxetine. Expert Opin Pharmacother 2008; 9: 787-794
    CrossrefPubMedGoogle Scholar
  • 26 Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259-1272
    Google Scholar
  • 27 Bobo WV, Shelton RC. Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 2009; 10: 2145-2159
    CrossrefPubMedGoogle Scholar
  • 28 Bellani M, Dusi N, Yeh PH et al. The effects of antidepressants on human brain as detected by imaging studies. Focus on major depression. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1544-1552
    CrossrefPubMedGoogle Scholar
  • 29 Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-475
    CrossrefPubMedGoogle Scholar
  • 30 Thase ME, Shelton RC, Khan A. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies. J Clin Psychopharmacol 2006; 26: 250-258
    CrossrefPubMedGoogle Scholar
  • 31 Müller N, Schennach R, Riedel M et al. Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Rev Neurother 2008; 8: 527-536
    CrossrefPubMedGoogle Scholar
  • 32 Benjamin S, Doraiswamy PM. Review of the use of mirtazapine in the treatment of depression. Expert Opin Pharmacother 2011; 12: 1623-1632
    CrossrefPubMedGoogle Scholar
  • 33 Dhillon S, Yang LP, Curran MP. Bupropion: a review of its use in the management of major depressive disorder. Drugs 2008; 68: 653-689
    CrossrefPubMedGoogle Scholar
  • 34 Javelot T, Javelot H, Baratta A et al. Acute psychotic disorders related to bupropion: review of the literature. Encephale 2010; 36: 461-471
    CrossrefPubMedGoogle Scholar
  • 35 Moreira R. The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clin Drug Investig 2011; 31 (Suppl. 01) 5-17
    CrossrefPubMedGoogle Scholar
  • 36 Hewett K, Gee MD, Krishen A et al. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol 2010; 24: 1209-1216
    CrossrefPubMedGoogle Scholar
  • 37 Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2011; epub ahead of print
    PubMedGoogle Scholar
  • 38 De Berardis D, Di Iorio G, Acciavatti T et al. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine. CNS Neurol Disord Drug Targets 2011; 10: 119-132
    CrossrefPubMedGoogle Scholar
  • 39 Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000; 58: 19-36
    CrossrefPubMedGoogle Scholar
  • 40 Adli M, Baethge C, Heinz A et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
    CrossrefPubMedGoogle Scholar
  • 41 Stahl SM, Felker A. Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. CNS Spectr 2008; 13: 855-870
    PubMedGoogle Scholar
  • 42 Ben-Arie O, George GC. A case of tranylcypromine (“Parnate”) addiction. Br J Psychiatry 1979; 135: 273-274
    CrossrefPubMedGoogle Scholar
  • 43 Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-494
    CrossrefPubMedGoogle Scholar
  • 44 Köhler S, Bauer M, Adli M. Behandlungsstrategien der therapieresistenten Depression. Psychiatrie und Psychotherapie up2date 2012; 6: 137-148
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
    CrossrefPubMedGoogle Scholar
  • 46 Köhler S. Vergleich medikamentöser Behandlungsstrategien bei Patienten mit unipolarer Depression und primärem Therapieversagen in einem stationären Setting. Dresden: Medizinische Fakultät der Technischen Universität Carl Gustav Carus; 2011: 150
    PubMedGoogle Scholar
  • 47 Bschor T, Baethge C. No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 2010; 121: 174-179
    CrossrefPubMedGoogle Scholar
  • 48 Souery D, Serretti A, Calati R et al. Citalopram versus desipramine in treatment resistant depression: effect of continuation or switching strategies: a randomized open study. World J Biol Psychiatry 2011; 12: 364-375
    CrossrefPubMedGoogle Scholar
  • 49 Blier P, Gobbi G, Turcotte JE et al. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. Eur Neuropsychopharmacol 2009; 19: 457-465
    CrossrefPubMedGoogle Scholar
  • 50 Blier P, Ward HE, Tremblay P et al. Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry 2010; 167: 281-288
    CrossrefPubMedGoogle Scholar
  • 51 Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354: 1243-1252
    CrossrefPubMedGoogle Scholar
  • 52 Rush AJ, Trivedi MH, Stewart JW et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry 2011; 168: 689-701
    CrossrefPubMedGoogle Scholar